| ORPH - Orphazyme AS ADR (Healthcare: Biotechnology) | Projected Earnings Date: 0000-02-29 (Delayed quote data ) |
|
|
|||||||||||||||||
|
|
|
| Company Profile | |
| Orphazyme AS is a late-stage biopharmaceutical company harnessing the amplification of Heat Shock Proteins. It is engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for four severe orphan diseases: Niemann-Pick disease Type C (NPC), Gaucher disease, Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM). | |
| Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. |